Literature DB >> 3350243

Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells.

H J Broxterman1, H M Pinedo, C M Kuiper, L C Kaptein, G J Schuurhuis, J Lankelma.   

Abstract

A marked increase in cellular ATP consumption was induced by verapamil in the multidrug-resistant (MDR) cell line 2780AD, but not in the drug-sensitive parental cell line A2780. A group of structurally unrelated drugs in concentrations known to reverse MDR, but not the verapamil analog tiapamil, a weak modulator of MDR, had similar effects. This effect was saturated at verapamil concentrations of about 1 microM. These data demonstrate that verapamil concentrations in MDR cells are maintained at a low level at the expense of ATP hydrolysis, and provide a first indication of the amount of metabolic energy used in this process.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3350243     DOI: 10.1096/fasebj.2.7.3350243

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  27 in total

Review 1.  Collateral sensitivity as a strategy against cancer multidrug resistance.

Authors:  Kristen M Pluchino; Matthew D Hall; Andrew S Goldsborough; Richard Callaghan; Michael M Gottesman
Journal:  Drug Resist Updat       Date:  2012-04-06       Impact factor: 18.500

2.  Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges".

Authors:  Yoonseok Kam; Tuhin Das; Haibin Tian; Parastou Foroutan; Epifanio Ruiz; Gary Martinez; Susan Minton; Robert J Gillies; Robert A Gatenby
Journal:  Int J Cancer       Date:  2014-09-02       Impact factor: 7.396

Review 3.  The Evolution and Ecology of Resistance in Cancer Therapy.

Authors:  Robert Gatenby; Joel Brown
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

4.  Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer.

Authors:  Pedro M Enriquez-Navas; Yoonseok Kam; Tuhin Das; Sabrina Hassan; Ariosto Silva; Parastou Foroutan; Epifanio Ruiz; Gary Martinez; Susan Minton; Robert J Gillies; Robert A Gatenby
Journal:  Sci Transl Med       Date:  2016-02-24       Impact factor: 17.956

5.  Evolutionary approaches to prolong progression-free survival in breast cancer.

Authors:  Ariosto S Silva; Yoonseok Kam; Zayar P Khin; Susan E Minton; Robert J Gillies; Robert A Gatenby
Journal:  Cancer Res       Date:  2012-10-12       Impact factor: 12.701

Review 6.  Evolutionary strategy for systemic therapy of metastatic breast cancer: balancing response with suppression of resistance.

Authors:  Yoonseok Kam; Tuhin Das; Susan Minton; Robert A Gatenby
Journal:  Womens Health (Lond)       Date:  2014-07

Review 7.  Life history trade-offs in cancer evolution.

Authors:  C Athena Aktipis; Amy M Boddy; Robert A Gatenby; Joel S Brown; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2013-11-11       Impact factor: 60.716

Review 8.  Tumour heterogeneity and the evolutionary trade-offs of cancer.

Authors:  Jean Hausser; Uri Alon
Journal:  Nat Rev Cancer       Date:  2020-02-24       Impact factor: 60.716

Review 9.  Is resistance useless? Multidrug resistance and collateral sensitivity.

Authors:  Matthew D Hall; Misty D Handley; Michael M Gottesman
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

10.  Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance.

Authors:  F S Clark; T Parkinson; C A Hitchcock; N A Gow
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.